Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 3/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1318206 | 1.00 | LMNA (0.48) | LMNACYP1A2CYP2D6MAPTHRH4 | |
| SCHEMBL1317316 | 0.85 | CCNC (0.37) | LMNAHRH4KMT2AHRH3 | |
| SCHEMBL1318247 | 0.83 | LMNA (0.43) | LMNACYP1A2CYP2D6MAPTHRH4 | |
| SCHEMBL1318681 | 0.81 | LMNA (0.41) | LMNACYP1A2CYP2D6MAPTHRH4 | |
| SCHEMBL1318986 | 0.81 | LMNA (0.41) | LMNACYP1A2CYP2D6MAPTHRH4 | |
| SCHEMBL1318984 | 0.81 | LMNA (0.41) | LMNACYP1A2CYP2D6MAPTHRH4 | |
| SCHEMBL3195271 | 0.80 | HRH4 (0.57) | HRH4HRH3 | |
| SCHEMBL3199906 | 0.80 | HRH4 (0.54) | HRH4HRH3 | |
| SCHEMBL6023882 | 0.79 | LMNA (0.56) | LMNACYP1A2CYP2D6MAPTHRH4 | |
| SCHEMBL5076739 | 0.79 | LMNA (0.56) | LMNACYP1A2CYP2D6MAPTHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | LMNA 4686/4885CYP1A2 1859/4885CYP2D6 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.